Healthcare
KORU Medical Systems, Inc.(KRMD)
Live Price
Offline$4.00
+0.00% today
1Y Change
+8.38%
Window
Jun 26, 2025 โ Jun 17, 2026
- Market Cap
- $190.00M
- Revenue Growth
- +22.2%
- EPS Growth
- +56.1%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 26, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
KORU Medical Systems, Inc. (KRMD) is a Healthcare stock with a market cap of $190.00M and listed on NASDAQ. The stock last traded around $4.00 and up 8.4% across the available one-year price window (Jun 26, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +22.2%, EPS growth of +56.1%, a dividend yield of 0.0%. What stands out right now is revenue +22.2%, EPS +56.1%, free cash flow +70.9% with operating margin -6.7% and ROIC -13.5%. Valuation sits in the middle of the pack at price/sales 4.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines KRMD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+22.2% vs +7.6% peer median
Operating Margin
Below sector median
-6.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report was closer to in-line
2026 was reported on May 6, 2026 with revenue ahead of estimates by +4.3%.
The operating story is still moving forward
Revenue is running at +22.2% and EPS at +56.1%, with operating margin around -6.7%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 5, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | +0.0% | +10.7% | -4.0% | +3.2% |
2026 Mar 12, 2026 | +50.0% | -0.7% | -0.2% | -2.3% |
2025 Nov 12, 2025 | +33.3% | +15.1% | +15.1% | +55.0% |
Benchmark Edge
KRMD vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
KRMD
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
KRMD Max Drawdown
-41.26%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for KRMD and SPY.
Company Overview
KORU Medical Systems, Inc.
NASDAQ Capital Market
KORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. It offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company also provides education and training materials to clinicians, patients, and patient advocates. It sells its products through direct sales and medical device distributors, as well as online. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York.
- Leadership
- Linda Tharby
- IPO Date
- Apr 5, 1994
- Employees
- 80
- Street Address
- 24 Carpenter Road
- Mailing
- Mahwah, NY, 10918
- Region
- Mahwah, NY, US
- Reporting Currency
- USD
- Investor Line
- 845 469 2042
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 4.6
- Price/Book
- 11.0
Growth
- Revenue
- +22.2%
- EPS
- +56.1%
- Free Cash Flow
- +70.9%
Profitability
- Gross Margin
- 60.3%
- Operating Margin
- -6.7%
- Net Margin
- -6.4%
- ROE
- -15.9%
- ROIC
- -13.5%
Balance Sheet
- Debt/Equity
- 0.21
- Current Ratio
- 2.44
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.